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Immunogenicity of biopharmaceuticals is complex and influenced by both structural and
pharmacological factors, and by patient-related conditions such as disease being treated,
previous and concomitant therapies, and individual immune responsiveness. Essential for
tailored therapeutic strategies based on immunopharmacological evidence from individ-
ual patients (personalized medicine) is the use of assays for anti-drug antibodies (ADA)
that are accurate and relevant in the clinical setting. This paper discusses immunogenicity
of genetically engineered immunoglobulins directed against tumor-necrosis factor-α (TNF).
Emphasis will be on commonly used methods for detection of ADA in human serum includ-
ing issues that question the clinical applicability of these methodologies.The use of dubious
assays for ADA in a clinical context may not only contribute to confusion as to the impor-
tance of drug immunogenicity but may also prevent development of safe and cost-effective
ways of using biological TNF-antagonists.
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INTRODUCTION
Immunogenicity is a risk associated with all genetically engineered
proteins, and repeated injections of humanized biopharmaceu-
ticals may generate anti-drug antibodies (ADA), which can be
related to drug failure and side effects (1). Examples are swine and
human insulin, growth hormone, factor VIII, factor IX, erythro-
poietin, type I interferons, and a host of more or less “humanized”
antibody constructs (2). The latter include biopharmaceuticals
that target the inflammatory cytokine, tumor-necrosis factor-α
(TNF) (Figure 1) (3–5). It has, for example, been documented
repeatedly that the appearance of ADA against biological TNF-
antagonists is a frequent occurrence, and that this is closely asso-
ciated with disappearance of drug in the circulation, and response
failure (2, 6, 7).
The importance of individualization of therapies with protein
drugs has been increasingly recognized in recent years (7). This is
particularly important with administration of costly and widely
used biological drugs, where investigations suggest that therapeu-
tic decision making should be based on immunopharmacological
monitoring in addition to clinical outcome. A rational, but fre-
quently overlooked approach to accomplish this would be the use
of reliable and clinically relevant methods for ADA (and drug)
detection in biological fluids.
This paper briefly describes commonly used assays for circu-
lating ADA with focus on applicability as clinical tools to improve
anti-TNF therapies, including cost-effectiveness.
NEUTRALIZING AND NON-NEUTRALIZING ADA
Neutralizing ADA directly interferes with the ability of
biological TNF-inhibitors to block TNF signaling through spe-
cific TNF-receptors on target cells. These ADA may be directed
against idiotopes in (or outside) the TNF-binding fragments
(Fab) of the anti-TNF immunoglobulin construct (Figure 1).
Depending on binding characteristics such as affinity and asso-
ciation/dissociation kinetics, these anti-idiotypic antibodies may
directly prevent a drug from binding TNF. Neutralizing ADA may,
however, also result from ADA binding to other sites on the drugs,
for example, if binding of one or more ADA molecules result in
steric changes that prevent a drug from attaching to TNF, or if
ADA-binding results in drug aggregation and/or immune com-
plex formation that masks TNF-binding sites on individual drug
molecules.
Neutralizing ADA is generally thought to be more important
in the clinical setting than non-neutralizing ADA. The latter, how-
ever, may indirectly reduce therapeutic efficacy by compromising
bioavailability and/or accelerate drug clearance from the circu-
lation. Thus, in cases where TNF-antagonists are administered
subcutaneously, non-neutralizing (as well as neutralizing) ADA
may form immune complexes around injection sites reducing drug
transfer to the circulation. Non-neutralizing ADA may also alter
the pharmacokinetics (PK) of drugs influencing tissue availabil-
ity of TNF-antagonists through formation of immune complexes
and subsequent removal of drug from the circulation through
endothelial impact, spleen filtration, binding to Fcγ receptors on
phagocytic cells, and Brambell receptor-mediated recycling. All of
these processes are likely to be independent of the drug’s ability to
bind TNF, as are side effects caused by drug – ADA complexes.
TROUGH LEVEL ADA ASSESSMENTS
The conventional approach to test for ADA is to assess serum
samples collected at the end of a therapeutic cycle (trough levels).
This originates from the fact that almost all commonly used assays
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FIGURE 1 | Putative immunogenic sites on anti-TNF antibody
constructs. Antibody constructs, drugs, and drug fragments with
“human” aminoacid sequences, are depicted in red. Mouse sequences
are shown in black/gray. ADA, anti-drug antibody; CDR, complementarity-
determining variable region of antibody; CH1, CH3, CL, constant regions
of IgG on light- and heavy-chains, respectively; Fab, antigen-binding
region of antibody; Fc, crystallizable region of antibody; FR, framework
region of antibody; TNF, tumor-necrosis factor; TNF-R2, TNF type 2, p75
receptor; VH, VL, variable regions of IgG on heavy and light chains,
respectively.
are drug-sensitive, so that they cannot accurately detect ADA in
blood collected closer to drug administration (8). Unfortunately,
measuring trough levels of ADA limits the clinical usefulness of
the test results. This is because trough is often ill-defined. Drug
holidays, for example, are sometimes needed in patients with inter-
current diseases, or just for practical reasons. Assessing trough
levels of ADA under these circumstances, i.e., long after drug
administration, may result in higher than “normal” levels, par-
ticularly if immunization has progressed from a primary immune
response to a prolonged and more potent secondary response.
Therapeutic failure may also lead to trials with shortened intervals
of drug administration, which would result in lower than“normal”
trough levels of ADA due to rapid removal from the circulation of
newly formed drug – ADA complexes.
Assessment of immunogenicity of TNF-antagonists is also
affected by different dosing intervals. Etanercept, for example, is
administered once weekly, and this frequent administration results
in high drug levels even in trough samples, making it difficult for a
drug-sensitive test to reveal the presence of anti-etanercept ADA.
An approach to overcome this problem would be to separate
drug – antibody complexes before or during the assay. This may be
accomplished by acid dissociation of immune complexes (9). In a
variant of this assay, adapted for detection of ADA against adal-
imumab, the immune complexes are dissociated by adding acid
and rabbit anti-idiotype-F(ab) (10). The rabbit F(ab) fragments
inhibit reformation of ADA – drug complexes by competing with
ADA for drug binding. Released ADA is then measured by an
antigen-binding radioimmunoassay. Unfortunately, these assays
are laborious and difficult to adapt to routine use if carried out
by radioimmunoassay. Incomplete dissociation of the immune
complexes and/or reassociation before completion of the assay
are other potential problems. The process of pH-shifting during
testing may also introduce artifacts that are difficult to control,
including irreversible destruction of ADA-binding epitopes on
drug molecules in vivo.
Another approach would be to develop techniques for more
robust PK analyses instead of those deducted from PK surrogates
in trough serum samples. This is now possible with the develop-
ment of reporter-gene assays (RGA) that monitor TNF-mediated
activation of TNF-receptor-bearing target cells; see below. This
enables detection of TNF neutralization (provided by the drug)
and neutralization of this effect (by ADA). Such a cell-based assay
would mirror processes at the cellular level in vivo, and it might
be used to assess anti-TNF activities in the blood at drug delivery
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and at various times thereafter. It is, for example, likely that peak
TNF-inhibitory activity in a therapeutic cycle would provide more
information of clinical relevance than trough drug and ADA levels.
PROBLEMSWITH CURRENTLY USED ASSAYS FOR ADA
Assessing ADA is especially difficult when testing binding of ADA
directed against drugs that are also antibodies. In these cases,
standard laboratory techniques may fail to provide accurate and
clinically useful results (8). The most commonly used assays
include various modifications of the enzyme-linked immunosor-
bent assay (ELISA). Unfortunately, however, rheumatoid factors,
anti-allotypic antibodies, and heterophilic antibodies may inter-
fere with readout in these assays. In addition, the frequently used
bridging-type ELISA (bELISA) fail to detect IgG4 ADA, which
may dominate after prolonged immunizations (Figure 2). Finally,
all solid-phase techniques are sensitive to artifacts such as epi-
tope shielding and neoepitope formation because protein drugs,
including anti-TNF biopharmaceuticals, may aggregate on plastic
surfaces (7).
Less artificial fluid-phase techniques, for example, certain
radioimmunoassays, better reflect the in vivo conditions and are
therefore considered more robust in the clinical setting providing
fewer false-negative and false-positive results, which is essential
when an assay is used for individual therapeutic guidance (5–7).
A shortcoming of all binding assays is that they do not distin-
guish between inactive (non-neutralizing) and functionally active
(neutralizing) ADA. This is essential for a more precise under-
standing of why therapies fail in some patients and not in others, as
recognized by regulatory authorities1. For example, routine bind-
ing assays do not inform about binding kinetics and whether or
not an observed attachment between drug and ADA is capable of
reducing the drug’s ability to compete with high-affinity cellular
TNF-receptors in a manner that prevents TNF-induced signaling
in vivo. Another shortcoming of binding assays for ADA is the
lab-to-lab variations between these techniques. This underscores
the requirement for universal ADA standards when comparing
binding-data from different laboratories.
With this in mind and realizing the artificial setup of most
solid-phase techniques in general, it is plausible that the wide use
of these assays for ADA detection have contributed to the current
uncertainty surrounding drug immunogenicity. Unfortunately,
this confusion may continue if clinical relevance of technolo-
gies used for therapeutic monitoring is ignored. Newly developed
solid-phase binding assays, including those based on chip and bead
technologies, may have similar draw-backs as they report antibody
binding to drugs in an aggregated or otherwise denatured form.
ASSAYS FOR BINDING ADA
Enzyme-linked immunosorbent assays are the most commonly
used tests for ADA in patient serum. There are two major
variations, sandwich ELISA and bELISA:
1. Sandwich ELISA detects ADA in serum by their ability to
bind to plastic-immobilized Fab or Fab2 fragments of the
1http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/
2009/09/WC500003946.pdf
antibody-derived anti-TNF drug. This assay is affordable and
easy to use. It is, however, a potential problem that binding takes
place to a drug attached to a plastic surface in a more or less
aggregated form, as this increases the risk of neoepitope for-
mation and epitope shielding (11). False-positive results have
been observed if washing procedures are insufficient during
testings, as this enables “sticky” Fc-fragments of antibodies to
cross-bind to immobilized antibody-derived drug irrespective
of specificities (11).
2. The bELISA modification is shown in Figure 2A. This
assay depends on the bivalency or multivalency of all major
immunoglobulin classes of ADA. It is sensitive and relatively
easy to setup and use. Unfortunately, however, this method-
ology has significant draw-backs when used in the clinical
setting. False-positive ADA results may, for example, arise
from cross-binding of drug Fc-fragments by rheumatoid fac-
tor, anti-allotypic antibodies, and/or low-affinity antibodies,
including heterophilic antibodies in patient sera. This technol-
ogy also fails to detect IgG4 ADA, an IgG isotype that dominates
after prolonged immunizations (12, 13). This is because IgG4
antibodies are functionally monovalent and therefore cannot
“bridge” in this type of binding assay (Figure 2A). More impor-
tantly for accurate patient monitoring is the fact that bELISA is
highly drug-sensitive with a risk of false-negative findings (7, 8).
Some investigators report ADA status as “inconclusive” if drug
is detectable in sera testing negative for ADA using bELISA.
This has been estimated to be the case in up to half the patients
in the clinical setting.
In addition to the above shortcomings, all solid-phase assays
have several noteworthy limitations. These include difficulties
for capture ELISA to detect anti-idiotypic antibodies because
idiotopes in the TNF-binding site(s) of biological TNF-antagonists
are concealed by plastic-immobilized TNF in the capture phase of
the assay (7).
Homogeneous mobility-shift assay (HMSA) uses size exclusion
high-performance liquid chromatography to determine serum
levels of ADA (Figure 2B). This technology has been introduced
in North America as a replacement for ELISA (14). The clini-
cal usefulness of HMSA is currently investigated, but its expen-
sive setup may limit routine use. It is a potential problem that
immune complexes may be artificially split during chromatogra-
phy. This will report antibodies that are non-neutralizing in vivo
because they circulate as drug – ADA immune complexes. A recent
study supports this, as the majority of HMSA-reported ADA in
infliximab-treated patients was functionally inactive judged by
parallel testings for neutralizing ADA (5).
CELL-BASED ASSAYS FOR NEUTRALIZING ADA
If an appropriate assay is available, regulatory authorities rec-
ommend that cell-based assays be used to quantify neutralizing
ADA against therapeutic proteins2. In the case of neutralizing
ADA against TNF-antagonists, such assays are usually based on
the ability of TNF to kill susceptible cell lines. These assays are,
2http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory
Information/Guidances/UCM192750.pdf
www.frontiersin.org April 2015 | Volume 6 | Article 109 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bendtzen Immunogenicity of TNF-antagonists: ADA detection
FIGURE 2 | Methods for ADA detection – and shortcomings.
(A) bELISA for drug-binding ADA. bELISA depends on the bivalency of
IgG ADA (and multivalency of IgA and IgM ADA) and therefore the ability
of these immunoglobulins to “bridge” drug molecules preadsorbed to a
plastic well with an added enzyme-labeled drug molecule (left panel). Note
that IgG4 antibodies are usually bispecific because half molecules are
exchanged after synthesis. They are therefore “invisible” in bELISA (right
panel). (B) HMSA for drug-binding ADA. HMSA depends on association
of fluorescence-labeled drug added to serum and subsequent
chromatographic separation of ADA-bound and free tagged drug (left
panel). Note that functionally inactive ADA, bound to drug in vivo, may be
split during assay and reassociated with tagged drug before or during
chromatography (right panel), thus reporting similar data as visualized in
the left panel. (C) RGA for neutralizing ADA. RGA reports functional levels
of all classes of drug-neutralizing ADA and, in addition, functional levels of
all currently used anti-TNF drugs. When human recombinant TNF is added
to the target cells, the cytokine initiates intracellular signaling through the
surface TNF-receptor, type 1 (TNF-R1), thus activating the cytoplasmic
nuclear factor (NF)-κB. The active components of this transcription factor
are then transported into the nucleus where they bind to NF-κB response
elements (NF-κB-REs) in the genome. This activates more than a hundred
genes, including an inserted reporter-gene construct encoding the enzyme
Firefly luciferase. After cell lysis and addition of substrate,
luciferase-catalyzed light emission can be quantified. When TNF is
preincubated with patient serum containing an anti-TNF drug and then
added to the cells (step 1 mid), the drug, if functional, neutralizes the
effect of TNF, and no intracellular signal is initiated. When TNF is
preincubated with patient serum containing drug-neutralizing ADA and
then added to the cells (step 1 right), the drug no longer interferes with
TNF-mediated signaling, resulting in a luminescence signal.
however, difficult to standardize, take days to complete, are subject
to serum matrix effects, and require cell-growth facilities. They are
also limited by the fact that factors in patient sera may interfere
with the assay outcome.
Reporter-gene assay is the most recent development in the
efforts to assess ADA against TNF-inhibitors in a clinical con-
text (15) (Figure 2C). It is a cell-based assay, which does not have
the same characteristics as common binding assays such as ELISA
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and HMSA. Unlike these assays, RGA detects TNF activity, not
drug or ADA sui generis (7). Rather, it gives a functional assess-
ment of biologically active drug counteracted by ADA, but only
if the latter bind with sufficient avidity to a locality (epitope) on
the drug that enables interference with TNF-R-mediated intra-
cellular signaling (neutralizing ADA). This closely resembles the
conditions under which TNF-antagonists are believed to function
in vivo.
Known limitations of cell-based assays have been overcome by
construction of an internally normalized RGA that allows quan-
tifications independent of serum matrix effects and cell-numbers
(15). The use of assay-ready cells stored at −80°C also obviates
the need for cell cultivation. Though less sensitive than certain
binding assays, notably radioimmunoassay, and HMSA, RGA per-
forms well in the clinical setting (5). It is highly specific for TNF,
and is easily modified to monitor patients treated with all known
anti-TNF biopharmaceuticals.
CONCLUSION AND PERSPECTIVE
• Most biological TNF-antagonists are immunogenic even if
claimed to be “fully human.”
• A prerequisite for rational long-term use of these drugs is guid-
ance by accurate assessments of functional ADA (and drug) in
the circulation, if not routinely then every time therapy fails or
side-effects occur.
• Binding assays have important limitations in the clinical setting.
This is primarily due to the artificial nature of these methods and
drug-sensitivity, resulting in false-negative ADA assessments.
• ADA detected by high-sensitivity binding assays such as radioim-
munoassay and HMSA are often non-neutralizing in vivo and
therefore of questionable therapeutic relevance.
• Regulatory authorities recommend that cell-based assays be used
to quantify neutralizing ADA against therapeutic proteins.
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